The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study

The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study

Abstract Background Numerous studies have investigated the potential association of sodium-glucose co-transporter-2 inhibitors (SGLT2-Is) with an increased risk of lower limb amputations (LLAs), but have produced conflicting results. Particularly studies comparing SGLT2-Is to glucagon-like peptide-1...

Full description

Bibliographic Details
Main Authors: Nikki C. C. Werkman, Johanna H. M. Driessen, Coen D. A. Stehouwer, Peter Vestergaard, Nicolaas C. Schaper, Joop P. van den Bergh, Johannes T. H. Nielen
Format: Article
Language:English
Published: BMC 2023-06-01
Series:Cardiovascular Diabetology
Subjects:
Type 2 diabetes
Sodium-glucose co-transporter-2 inhibitors
Glucagon-like peptide-1 receptor agonists
Amputations
Diabetic foot ulcer
Cohort study
Online Access:https://doi.org/10.1186/s12933-023-01897-2

Internet

https://doi.org/10.1186/s12933-023-01897-2

Similar Items